Literature DB >> 17505821

The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid.

P R Donald1, D P Parkin, H I Seifart, H S Schaaf, P D van Helden, C J Werely, F A Sirgel, A Venter, J S Maritz.   

Abstract

OBJECTIVE: This study evaluated the pharmacokinetics of isoniazid (INH) associated with optimal early bactericidal activity (EBA), defined as 90% of the maximum EBA (EBA(90)) and the influence of N-acetyltransferase-2 (NAT2) subtype on the ability of pulmonary tuberculosis (PTB) patients to reach the identified pharmacokinetic values after INH doses ranging from 0.2 to 10-12 mg/kg body weight.
METHODS: INH serum concentrations and NAT2 subtype were determined during four studies of PTB patients in three of whom the EBA of INH was determined. The relationship of EBA to area under the curve (AUC) (AUC(0-infinity)) and 2-h serum concentrations was examined by exponential regression and fitted curves estimated the AUC(0-infinity) and 2-h serum concentrations at which EBA(90) was reached.
RESULTS: EBA(90) was reached at an AUC(0-infinity) of 10.52 microg/ml per hour and 2-h serum concentrations of 2.19 microg/ml. An AUC(0-infinity) of 10.52 microg/ml per hour was reached by all 66 patients receiving a 10-12 mg/kg INH dose and all 21 receiving 6 mg/kg, except 1 of 10 (10%) homozygous fast (FF) acetylators; however, at 5 mg/kg, 4 of 12 (33%) FF and 26 of 27 (96%) heterozygous fast (FS), but all 21 homozygous slow (SS) acetylators did so; and 1 of 3 (33%) FF, 2 of 6 (33%) FS, but all 4 SS acetylators at dose 3 mg/kg. An INH 2-h serum concentration of 2.19 microg/ml was reached by all 66 patients receiving 10-12 mg/kg and all 21 receiving 6 mg/kg, except for 2 (20%) FF acetylators at a dose of 5 mg/kg; however, only 3 (25%) of 12 FF acetylators, but 26 (96%) of 27 FS acetylators, and all 21 SS acetylators reached this concentration; and at a dose of 3 mg/kg, 1 (33%) of 3 FF acetylators, 2 (33%) of 6 FF, but all 4 SS acetylators.
CONCLUSIONS: At a 6 mg/kg dose, all except a minority of FF NAT2 acetylators, achieve an INH AUC(0-infinity) and 2-h INH serum concentrations associated with EBA(90), as did all 4 SS acetylators receiving 3 mg/kg. Any dose reduction below 6 mg/kg body weight will tend to disadvantage a significant proportion of faster acetylators, but, conversely, SS acetylators require only a 3 mg/kg dose to achieve a satisfactory exposure to INH.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17505821     DOI: 10.1007/s00228-007-0305-5

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   3.064


  30 in total

1.  Combined drug treatment of tuberculosis. III. Clinical application of the principles of appropriate and adequate chemotherapy to the treatment of pulmonary tuberculosis.

Authors:  W F RUSSELL; I KASS; A D HEATON; S H DRESSLER; G MIDDLEBROOK
Journal:  J Clin Invest       Date:  1959-08       Impact factor: 14.808

2.  Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis.

Authors:  H B HUGHES; J P BIEHL; A P JONES; L H SCHMIDT
Journal:  Am Rev Tuberc       Date:  1954-08

3.  Genotyping of the N-acetyltransferase2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients.

Authors:  Masahiro Hiratsuka; Yukinaga Kishikawa; Yoh Takekuma; Masaki Matsuura; Kaori Narahara; Tomoko Inoue; Samar Ismail Hamdy; Naomi Endo; Junichi Goto; Michinao Mizugaki
Journal:  Drug Metab Pharmacokinet       Date:  2002       Impact factor: 3.614

4.  The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis.

Authors:  P R Donald; F A Sirgel; F J Botha; H I Seifart; D P Parkin; M L Vandenplas; B W Van de Wal; J S Maritz; D A Mitchison
Journal:  Am J Respir Crit Care Med       Date:  1997-09       Impact factor: 21.405

5.  Hydrazine derivatives of isonicotinic acid (rimifon marsilid) in the treatment of active progressive caseous-pneumonic tuberculosis; a preliminary report.

Authors:  E H ROBITZEK; I J SELIKOFF
Journal:  Am Rev Tuberc       Date:  1952-04

6.  Basic mechanisms of chemotherapy.

Authors:  D A Mitchison
Journal:  Chest       Date:  1979-12       Impact factor: 9.410

7.  The early bactericidal activity of drugs in patients with pulmonary tuberculosis.

Authors:  A Jindani; V R Aber; E A Edwards; D A Mitchison
Journal:  Am Rev Respir Dis       Date:  1980-06

8.  Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?

Authors:  Martina Kinzig-Schippers; Dorota Tomalik-Scharte; Alexander Jetter; Bernhard Scheidel; Verena Jakob; Michael Rodamer; Ingolf Cascorbi; Oxana Doroshyenko; Fritz Sörgel; Uwe Fuhr
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

9.  Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity.

Authors:  M Ohno; I Yamaguchi; I Yamamoto; T Fukuda; S Yokota; R Maekura; M Ito; Y Yamamoto; T Ogura; K Maeda; K Komuta; T Igarashi; J Azuma
Journal:  Int J Tuberc Lung Dis       Date:  2000-03       Impact factor: 2.373

10.  The early bactericidal activity of streptomycin.

Authors:  P R Donald; F A Sirgel; A Venter; E Smit; D P Parkin; B W Van de Wal; C J Doré; D A Mitchison
Journal:  Int J Tuberc Lung Dis       Date:  2002-08       Impact factor: 2.373

View more
  39 in total

Review 1.  An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.

Authors:  Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

Review 2.  Accessing and integrating data and knowledge for biomedical research.

Authors:  A Burgun; O Bodenreider
Journal:  Yearb Med Inform       Date:  2008

3.  Simultaneous analysis of 11 medications for drug resistant TB in small hair samples to quantify adherence and exposure using a validated LC-MS/MS panel.

Authors:  Roy Gerona; Anita Wen; David Aguilar; Jamie Shum; Andrew Reckers; Peter Bacchetti; Monica Gandhi; John Metcalfe
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2019-07-23       Impact factor: 3.205

4.  How long will treatment guidelines for TB continue to overlook variability in drug exposure?

Authors:  Morris Muliaditan; Oscar Della Pasqua
Journal:  J Antimicrob Chemother       Date:  2019-11-01       Impact factor: 5.790

5.  Population modeling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs.

Authors:  L Lalande; L Bourguignon; S Bihari; P Maire; M Neely; R Jelliffe; S Goutelle
Journal:  Antimicrob Agents Chemother       Date:  2015-06-15       Impact factor: 5.191

6.  Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid.

Authors:  Maxwell T Chirehwa; Helen McIlleron; Lubbe Wiesner; Dissou Affolabi; Oumou Bah-Sow; Corinne Merle; Paolo Denti
Journal:  J Antimicrob Chemother       Date:  2019-01-01       Impact factor: 5.790

Review 7.  [Treat to target and personalized medicine (precision medicine)].

Authors:  J Detert; G R Burmester
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

8.  Tuberculosis after gastrectomy, plasmatic concentration of antitubercular drugs.

Authors:  De Socio Giuseppe Vittorio; D'Avolio Antonio; Sgrelli Alessio; Baietto Lorena; Lisa Malincarne; Di Perri Giovanni; Baldelli Franco
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-01-24       Impact factor: 2.576

9.  Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation.

Authors:  Christopher Vinnard; Shruthi Ravimohan; Neo Tamuhla; Vijay Ivaturi; Jotam Pasipanodya; Shashikant Srivastava; Chawangwa Modongo; Nicola M Zetola; Drew Weissman; Tawanda Gumbo; Gregory P Bisson
Journal:  Br J Clin Pharmacol       Date:  2016-12-09       Impact factor: 4.335

10.  Time Trends in Sputum Mycobacterial Load and Two-Day Bactericidal Activity of Isoniazid-Containing Antituberculosis Therapies.

Authors:  Veronique De Jager; Lize van der Merwe; Amour Venter; Peter R Donald; Andreas H Diacon
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.